Empagliflozin Selected Cardiovascular and Safety Outcomes in Routine Care: First Results From the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study

Metabolism: Clinical and Experimental - Netherlands
doi 10.1016/j.metabol.2019.12.072
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pdb15 - Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase 4 (Dpp-4) Inhibitors: Systematic Literature Review and Indirect Comparisons

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pdb12 - Cardiovascular Safety of Empagliflozin Versus Glucagon-Like Peptide-1 (Glp-1) Receptor Agonists: Systematic Literature Review and Indirect Comparisons

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pdb76 - Cost-Effectiveness Analysis of Empagliflozin in Comparison to Liraglutide Based on Cardiovascular Outcome Trials

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Ce1 - Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Empagliflozin/Linagliptin Single-Tablet Combination: First-In-Class Treatment Option

International Journal of Clinical Practice
Medicine
2015English

TAS-102 Safety in Metastatic Colorectal Cancer: Results From the First Postmarketing Surveillance Study

Clinical Colorectal Cancer
OncologyGastroenterology
2016English

Empagliflozin in Type 1 Diabetes

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2019English

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Healthy Japanese Subjects

Drug Metabolism and Pharmacokinetics
PharmacologyPharmaceutical Science
2013English

Diabetische Ketoazidose Unter Empagliflozin

Swiss Medical Forum ‒ Schweizerisches Medizin-Forum
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy